Avalo Therapeutics AVTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -88.8%-16.3pp | -72.4%+105pp | -177.4%— | —— | —— | |
| Return on assets | -71.1%-12.5pp | -58.6%+30.8pp | -89.4%-50.0pp | -39.4%-95.0pp | 55.7%+96.6pp | |
| Liquidity | ||||||
| Current ratio | 7.7×-0.5× | 8.1×-6.1× | 14.3×+1.8× | 12.4×-10.2× | 22.6×+2.7× | |
| Quick ratio | 7.7×-0.5× | 8.1×-6.1× | 14.3×+1.8× | 12.4×-10.2× | 22.6×+2.7× | |
| Cash ratio | 2.2×+0.9× | 1.2×-2.2× | 3.4×-1.2× | 4.6×-17.7× | 22.3×+3.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -19.8×-3.0× | -16.8×-2.2× | -14.5×-0.9× | -13.6×-2.0× | -11.6×+9.1× | |
| Per Share | ||||||
| Book value per share | $3.40-45.2% | $6.20-5.3% | $6.54-32.3% | $9.66-17.2% | $11.66-34.3% | |
| Valuation | ||||||
| Market capitalization | $946.18M+1,783% | $329.31M+97.0% | $167.17M+212% | $53.6M-37.3% | $85.48M+10.0% | |
| Enterprise value | $921.19M-1,342% | $313.63M+123% | $140.46M+1,095% | $11.76M+130% | -$38.96M+30.5% | |
| Price / book | 13.8×+13.4× | 4×+2.1× | 1.8×+1.3× | 0.5×-0.2× | 0.7×+0.1× | |
| Earnings yield | -9%-154pp | -23.8%+36.0pp | -59.7%+26.5pp | -86.2%-172pp | 85.4%+131pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's profit margins?
- Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
- Where do Avalo Therapeutics's ratios come from?
- Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
